BigHat Bio
Steve is an expert in protein engineering with over 20 years of experience in the design and development of antibody, cytokine, and fusion protein drugs. After receiving a PhD in Cell Biology at Johns Hopkins University School of Medicine and postdoctoral training at UC Berkeley, he held positions at successful biotech companies including Director Cell Biology at Exelixis and was VP, Research at Xencor, FivePrime Therapeutics, and Xoma. He most recently served as Chief R&D Officer at Nektar Therapeutics. Steve sits on the Board of Directors of Dicerna, and the Biotechnology Advisory Board of the University of Delaware.
This person is not in the org chart
This person is not in any offices
BigHat Bio
1 followers
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.